相似文献
1
Matrix Metalloproteinases in Health and Disease 3.0.
Biomolecules. 2024 Aug 26;14(9):1059. doi: 10.3390/biom14091059.
2
Matrix Metalloproteinases in Health and Disease.
Biomolecules. 2020 Aug 1;10(8):1138. doi: 10.3390/biom10081138.
3
Matrix metalloproteinases in skeletal muscles: friends or foes?
Neurobiol Dis. 2012 Dec;48(3):508-18. doi: 10.1016/j.nbd.2012.07.023. Epub 2012 Aug 3.
4
Matrix metalloproteinases (MMPs) in health and disease: an overview.
Front Biosci. 2006 May 1;11:1696-701. doi: 10.2741/1915.
5
Matrix Metalloproteinases in Health and Disease 2.0.
Biomolecules. 2022 Aug 27;12(9):1190. doi: 10.3390/biom12091190.
6
Role of Matrix Metalloproteinases in Degenerative Kidney Disorders.
Curr Med Chem. 2018;25(15):1805-1816. doi: 10.2174/0929867325666171205143441.
7
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.
Circ Res. 2003 May 2;92(8):827-39. doi: 10.1161/01.RES.0000070112.80711.3D.
8
Matrix metalloproteinases and atherosclerosis.
Curr Atheroscler Rep. 2004 Mar;6(2):112-20. doi: 10.1007/s11883-004-0099-1.
9
[The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis].
Postepy Hig Med Dosw (Online). 2012 Sep 10;66:609-28. doi: 10.5604/17322693.1009705.
10
Matrix Metalloproteinases and Platelet Function.
Prog Mol Biol Transl Sci. 2017;147:133-165. doi: 10.1016/bs.pmbts.2017.01.002. Epub 2017 Mar 21.
引用本文的文献
1
Limited Proteolysis as a Regulator of Lymphatic Vessel Function and Architecture.
Int J Mol Sci. 2025 Jul 24;26(15):7144. doi: 10.3390/ijms26157144.
2
Potential target within the tumor microenvironment - MT1-MMP.
Front Immunol. 2025 Mar 24;16:1517519. doi: 10.3389/fimmu.2025.1517519. eCollection 2025.
3
Identification of Alterations in the Expression of Genes Related to the Implant Failure in Spanish Patients with Down Syndrome and Periodontal Disease.
Genes (Basel). 2025 Jan 22;16(2):122. doi: 10.3390/genes16020122.
本文引用的文献
1
Expression of , , and genes in aortic dissection.
Exp Ther Med. 2024 Jul 10;28(3):360. doi: 10.3892/etm.2024.12649. eCollection 2024 Sep.
2
Comprehending the pharmacological mechanism of marine phenolic acids in bladder cancer therapy against matrix metalloproteinase 9 protein by integrated network pharmacology and in-silico approaches.
Comput Biol Chem. 2024 Oct;112:108149. doi: 10.1016/j.compbiolchem.2024.108149. Epub 2024 Jul 14.
3
ADAM15 in Fibroblasts: Improving the Matrix Remodeling by Blocking the Action of Transforming Growth Factor-β1.
Ann Clin Lab Sci. 2024 May;54(3):363-370.
4
Tissue Inhibitor of Metalloproteinase 3 (TIMP3) mutations increase glycolytic activity and dysregulate glutamine metabolism in RPE cells.
Mol Metab. 2024 Oct;88:101995. doi: 10.1016/j.molmet.2024.101995. Epub 2024 Jul 22.
5
Molecular immunological mechanisms of impaired wound healing in diabetic foot ulcers (DFU), current therapeutic strategies and future directions.
Int Immunopharmacol. 2024 Sep 30;139:112713. doi: 10.1016/j.intimp.2024.112713. Epub 2024 Jul 23.
6
Breaking the Cycle: Matrix Metalloproteinase Inhibitors as an Alternative Approach in Managing Tuberculosis Pathogenesis and Progression.
ACS Infect Dis. 2024 Aug 9;10(8):2567-2583. doi: 10.1021/acsinfecdis.4c00385. Epub 2024 Jul 22.
7
miR-126a-5p inhibits H1N1-induced inflammation and matrix protease secretion in lung fibroblasts by targeting ADAMTS-4.
Arch Virol. 2024 Jul 11;169(8):164. doi: 10.1007/s00705-024-06086-4.
8
The effect of ADAMTS13 on graft-versus-host disease.
J Cell Mol Med. 2024 Jul;28(13):e18457. doi: 10.1111/jcmm.18457.
9
Bergenin inhibits growth of human cervical cancer cells by decreasing Galectin-3 and MMP-9 expression.
Sci Rep. 2024 Jul 3;14(1):15287. doi: 10.1038/s41598-024-64781-3.
10
Metalloproteinases as Biomarkers and Sociomarkers in Human Health and Disease.
Biomolecules. 2024 Jan 11;14(1):96. doi: 10.3390/biom14010096.
Zotero 插件